Lifesaving therapy offers hope for patients with advanced heart failure, serving as a bridge to heart transplantation or long-term therapy. WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- MedStar Washington ...
Abbott Laboratories, Inc. ABT recently announced that the FDA has approved a change of label for its HeartMate 3 left ventricular assist device (LVAD or heart pump). The development, meant exclusively ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved updated labeling to remove aspirin as part of routine care after implant of Abbott’s fully ...
Abbott Laboratories announced a class I recall of the Heartmate 3 left ventricular assist system (LVAS) that affects nearly 890 units distributed over the past three years, a move triggered by reports ...
Pharmacotherapy for advanced heart failure patients with a HeartMate 3 left ventricular assist device (LVAD) is being simplified following US Food and Drug Administration approval of a labeling change ...
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
ABBOTT PARK, Ill., Aug. 29, 2022 /PRNewswire/ -- Abbott today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least ...
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients About Cadrenal Therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback